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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of acquired
immunodeficiency virus (AIDS). Following entry into the host cell, the viral RNA is reverse
transcribed into DNA and subsequently integrated into the host genome as a chromatin template.
The integrated proviral DNA, along with the specific chromatinized environment in which
integration takes place allows for the coordinated regulation of viral transcription and replication.
While the specific roles of and interplay between viral and host proteins have not been fully
elucidated, numerous reports indicate that HIV-1 retains the ability for self-regulation via the
pleiotropic effects of its viral proteins. Though viral transcription is fully dependent upon host
cellular factors and the state of host activation, recent findings indicate a complex interplay
between viral proteins and host transcription regulatory machineries including histone deacetylases
(HDACs), histone acetyltransferases (HATs), cyclin dependent kinases (CDKs), and histone
methyltransferases (HMTs).
Results: Here, we describe the effect of Tat activated transcription at the G1/S border of the cell
cycle and analyze the interaction of modified Tat with the chromatin remodeling complex, SWI/
SNF. HIV-1 LTR DNA reconstituted into nucleosomes can be activated in vitro using various Tat
expressing extracts. Optimally activated transcription was observed at the G1/S border of the cell
cycle both in vitro and in vivo, where chromatin remodeling complex, SWI/SNF, was present on the
immobilized LTR DNA. Using a number of in vitro binding as well as in vivo chromatin
immunoprecipitation (ChIP) assays, we detected the presence of both BRG1 and acetylated Tat in
the same complex. Finally, we demonstrate that activated transcription resulted in partial or
complete removal of the nucleosome from the start site of the LTR as evidenced by a restriction
enzyme accessibility assay.
Conclusion: We propose a model where unmodified Tat is involved in binding to the CBP/p300
and cdk9/cyclin T1 complexes facilitating transcription initiation. Acetylated Tat dissociates from
the TAR RNA structure and recruits bromodomain-binding chromatin modifying complexes such
as p/CAF and SWI/SNF to possibly facilitate transcription elongation.
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Background
Human immunodeficiency virus (HIV) is the etiological
agent of AIDS. The pathogenesis of HIV-induced disease is
complex and multifactorial [1]. Following infection,
reverse transcriptase complexes synthesize a double
stranded DNA molecule that is then incorporated into the
host genome. A robust cellular and humoral immune
response inhibits viral production within weeks. How-
ever, a chronic persistent infection in lymphoid tissue per-
sists throughout the life (median period of 10–20 years)
of the infected individual. Several key HIV-1 and cellular
proteins have been determined to be necessary for this
course of infection, including the trans-activator Tat. Viral
clones deficient in Tat do not effectively replicate in vitro
or in vivo. Furthermore, infected T cells quiescent at the G0
phase of the cell cycle (lacking cytokine signals) will not
produce high titer virus [2].
The replication rate of integrated HIV-1 is largely control-
led at the level of transcription. The HIV-1 LTR, present at
both ends of the integrated viral genome, contains cis-act-
ing elements necessary for transcription initiation from
the 5' LTR and for polyadenylation of the viral transcripts
in the 3' LTR. The core promoter of HIV-1 includes two
NF-κB binding sites, three Sp1 binding sites, the TATA
box, and the ligand-binding protein 1 (LBP-1)/YY1 site.
There is also a repressor complex sequence (RCS) within
the initiation site, which contains three binding motifs for
LSF. YY1 and LSF cooperate to allow binding of YY1 to the
RCS and subsequent recruitment of HDAC1 [3]. In addi-
tion to cellular transcription factors, the activity of the
HIV-1 promoter is strongly dependent on the viral trans-
activator, Tat. Historically, the mechanism of action by Tat
has been assigned to be at the level of initiation and elon-
gation [4-9]. The effect of Tat on pre-initiation, initiation,
and elongation has been observed through a number of
biochemical interactions, including physical binding to
Sp1[10], stabilization of the TFIID/TFIIA complex on the
HIV-1 TATA box [11], recruitment of a functional TATA-
binding protein (TBP) or TFIID [11-16], phosphorylation
of the carboxy-terminal domain (CTD) of RNA polymer-
ase II (RNAPII) by a number of kinases, including TFIIH
[17-19], hSpt5 which functions in transcription elonga-
tion as a stabilization factor of RNAPII [20], and binding
of Tat directly to RNAPII [21,22]. More recently the role of
Tat in transcription initiation has been revisited, where
Tat enhanced recruitment of TBP has been observed
resulting in activated transcription [23,24].
Tat activates the HIV LTR by binding to TAR and recruiting
and activating cellular factors [25-31]. One of the co-fac-
tors required for Tat activity is a protein kinase called TAK
(Tat-associated kinase) [32,33] whose activity is stimu-
lated by Tat. Activation of TAK (cdk9/cyclin T1) results in
hyper-phosphorylation of the large subunit of the RNAPII
CTD and activation of transcription elongation [34].
Cdk9 is analogous to a component of a positive acting
elongation factor (P-TEFb) isolated from Drosophila [35],
which acts to stimulate promoter-paused RNAPII to enter
into productive elongation [33,36-39]. A histidine-rich
stretch of cyclin T1 binds to the CTD of RNAPII, which is
required for the subsequent expression of full-length tran-
scripts from target genes [40]. Cdk9 phosphorylation is
required for high-affinity binding of Tat/P-TEFb to TAR
[41-43].
HIV-1 proviral DNA is organized into a higher order chro-
matin structure in vivo, which regulates viral expression by
restricting access of the transcriptional machinery to the
HIV-1 LTR. The primary chromatin structure of integrated
HIV-1 has been characterized in vivo by the DNase-1 diges-
tion method [44-46]. Two chronically infected human
cell lines, ACH2 (T-cell line) and U1 (promonocyte cell
line), were analyzed by DNase-I digestion and four dis-
tinct DNase-I hypersensitive sites (DHS) were identified
in the 5' LTR. It has been largely assumed that DHSs in the
native chromatin are free of histones and allow unre-
stricted access to DNA-binding proteins [47]. The first site,
DHS1, located at the 5' end of the integrated LTR, was
detected only as a minor DHS in U1 cells. DHS2 and
DHS3 are located in the U3 region, encompassing nt 223–
325 and nt 390–449, respectively. The NF-κB and Sp1
binding sites, as well as the TATA box, are located in DHS2
and DHS3. DHS4 was found immediately downstream of
the U5 region (nt 656–720), where a cluster of potential
transcription factor binding sites for AP-1, AP-3 like, DBF-
1, and Sp1 are positioned. The location of the DHSs was
also verified in vitro using the HIV-1 promoter reconsti-
tuted into chromatin by DNase-I footprinting analysis
[48-50]. Furthermore, independent of the viral integra-
tion site, five nucleosomes (nuc-0 to nuc-4) are precisely
positioned within the 5' LTR. In the transcriptionally
silent provirus, these nucleosomes define two large nucle-
osome-free regions spanning nt -255 to -3 and +141 to
+265. One nucleosome, nuc-1, is located between these
two regions. The first nucleosome-free region in U3 con-
tains many promoter/enhancer elements which are
already occupied by transcriptional factors including
repressors [51]. When cells are activated with TNF-α and
TPA treatment or with the HDAC-specific inhibitors, trap-
oxin, Trichostatin A (TSA), or sodium butyrate, DHS3 and
DHS4 are extended and nuc-1 is specifically remodeled.
Using a ChIP assay, histone acetylation surrounding nuc-
1 and the RCS was observed to be significantly increased
following TSA treatment [52]. The disruption of nuc-1
occurred independent of transcription and was α-amani-
tin insensitive, suggesting that this chromatin remodeling
was a pre-requisite for transcription, rather than a conse-
quence [46]. Therefore, the integrated proviral DNA,
along with the specific chromatinized environment inRetrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
Page 3 of 19
(page number not for citation purposes)
which integration takes place allows for the coordinated
regulation of viral transcription and replication. While the
specific roles of and interplay between viral and host pro-
teins have not been fully elucidated, numerous reports
indicate that HIV-1 retains the ability for self-regulation
via the pleiotropic effects of its viral proteins. Though viral
transcription is fully dependent upon host cellular factors,
recent findings indicate a complex interplay between viral
proteins and host transcription and signaling machineries
(i.e. HDACs, HATs, and other protein-modifying factors).
In the current manuscript, we describe the effect of Tat
activated transcription at the G1/S border of the cell cycle
and analyze the interaction of Tat with the chromatin
remodeling complex, SWI/SNF. HIV-1 LTR DNA reconsti-
tuted into nucleosomes can be activated in vitro using var-
ious Tat expressing extracts. More specifically, optimal
activated transcription was observed at the G1/S border of
the cell cycle both in vitro and in vivo. In an attempt to
define protein complexes that are normally involved in
HIV-1 transcription, we used an in vitro immobilized
nucleosomal DNA assembly system in the presence of the
G1/S extracts and pulled-down complexes followed by
their identification using MALDI-TOF mass spectrometry.
In addition to known factors such as Sp1, TFIIB, and cdk9/
cyclin T1, we also specifically detected the presence of
acetylated Tat and members of the SWI/SNF chromatin
remodeling complex. Using a number of in vitro binding
as well as in vivo ChIP assays, we detected the presence of
both BRG1 and acetylated Tat in the same complex.
Finally, we demonstrate that removal of nuc-1 resulted in
accessibility of the HIV-1 LTR DNA to a restriction enzyme
and activated transcription.
Results
Effect of Tat activation at the G1/S border
We previously demonstrated, by in vitro transcription
analysis, that Tat-dependent transcription takes place in a
cell cycle-dependent manner. We utilized cells that were
transfected with either a control plasmid (pCEP4) or a
hemagglutinin epitope-tagged Tat plasmid (eTat),
selected in hygromycin by single-cell dilution, and main-
tained in hygromycin. Whole-cell extracts were prepared
from control and eTat cells for in vitro transcription assays
using wild-type and mutant HIV-1 naked templates. Cells
at late G1/early S contained 10-fold higher levels of tran-
scriptional activity on the wild-type LTR template (LTR-
TAR+) than on the TAR mutant template (LTR-TAR-) [53].
Our previous results were performed with HIV-1 naked
LTR DNA; however, in vivo, the HIV-1 DNA is assembled
into organized nucleosomal DNA and the presence of
nucleosomes generally acts as an inhibitor of transcrip-
tion. Therefore, to closely mimic the in vivo scenario, we
decided to reconstitute HIV-1 LTR DNA into nucleosomes
and use the templates in an in vitro transcription reaction.
Nucleosomes were assembled on the HIV-1 LTR as previ-
ously described [48,54,55]. Following reconstitution,
extracts from various stages of cell cycle were used in an in
vitro transcription reaction. To obtain a uniform popula-
tion of cells, we treated both eTat and control cells first
with hydroxyurea, released, treated with nocodazole, fol-
lowed by release at various time points. Extracts were
made from the control and eTat cell lines at G0, early G1,
G1/S, late S, and G2 for in vitro transcription. Three types
of DNA were used in these assays, including HIV-LTR-TAR
wild-type, HIV-LTR-TAR mutant (TM26) (both assembled
into chromatin) and Adenovirus-Luc plasmid (AdLuc) as
a naked DNA control [55]. Transcription from the WT HIV
LTR was first observed with eTat extracts purified from the
G1 phase (Figure 1, left panel, lane 2). Transcription was
maximal at the G1/S border and declined during the S and
G2 phases (lanes 4 and 5). Very little detectable transcrip-
tion was observed with extracts obtained at the G0 (lane 1)
or in control extracts. Furthermore, no transcription was
observed when a TAR mutant template (TM26) was used
(lanes 11–15). These results indicate that HIV-1 transcrip-
tion started in the early G1 phase (lane 2); however, a
more robust activity was observed at the G1/S border (lane
3). In all cases ample transcription was observed using
naked AdLuc DNA. All HIV-1 DNAs still contained core
histones after transcription, indicating that nucleosomes
were still present (bottom panel). These results indicate
that robust Tat activated transcription begins at the G1/S
border of the cell cycle.
Presence of HIV-1 transcripts at the G1/S border in 
infected cells
To determine the timing of HIV-1 transcription, we meas-
ured the accumulation of two HIV-1 proteins (Nef and
Env), as well as cyclin E and cyclin A (positive controls) in
OM10.1 cells during various stages of the cell cycle. We
measured these proteins by a multiparametric flow cyto-
metric approach [56]. This technique allowed us to exam-
ine the accumulation of multiple proteins in individual
cells, as opposed to immunoblotting, which determines
the accumulation of proteins in a large, diverse cell popu-
lation. Furthermore, the flow cytometric approach allows
us to correlate this value with respect to the cell's position
in the cycle by measuring DNA content and multiple anal-
yses can be carried out in the same cell with different flu-
orescent markers. OM10.1 cells are a promyelocytic line
containing a transcriptionally latent, single copy of wild-
type HIV-1 integrated proviral DNA [57]. For cell cycle
analysis, these cells were initially arrested at G0 by feeding
with serum starvation medium for three days. Cells were
subsequently treated with TNF-α (10 ng/ml) for 2 h to
induce virus, washed, and incubated at 37°C with com-
plete medium. Samples (2/3) were collected at various
time points and analyzed using flow cytometry. TheRetrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
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remaining samples (1/3) were processed for RT-PCR using
primers for Env and Nef [58,59]. The positive controls,
cyclin E (hallmark of G1/S transcription) and cyclin A
(hallmark of S transcription), were detectable in OM10.1
cells (Figure 2A). More importantly, HIV-1 proteins,
namely Nef (from a doubly spliced transcript) and Env
(from a singly spliced transcript), were detected starting at
the G1/S phase of the cell cycle. RT-PCR assays show that
these samples display robust Env transcription at the G1/S
border (Figure 2A, bottom panel). Propidium iodide
staining of host DNA from various cell populations used
in antibody staining and RT-PCR analysis (Figure 2B)
demonstrated that the samples used in Figure 2A were at
particular phases of the cell cycle. These results are also
consistent with our previous work where we showed that
HLM-1 cells (HIV-1+/Tat-, [60]), which contain a single
copy of full-length HIV-1 provirus with a triple termina-
tion codon at the first AUG of the Tat gene, had dramati-
cally reduced levels of Gag/p24 antigen production when
arrested at G1/S [61].
Presence of chromatin remodeling factors on HIV-1 DNA 
at the G1/S border
To define some of the protein complexes that are nor-
mally involved in HIV-1 transcription, we utilized an in
vitro nucleosomal DNA assembly system, where the DNA
was labeled with biotin and bound to strepavidin beads
[62]. Subsequently, G1/S extracts were mixed with the
nucleosomal DNA and unbound material was washed
away. Retained complexes were separated on a 4–20%
SDS/PAGE and unique bands were used for MALDI-TOF
mass spectrometry (Figure 3). Four clade B LTR promoters
(nt -110 to +180) were used as controls, HXB2, pNL43,
LAI, and SF2. Also, nucleosomal templates were either
transcriptionally inactive (no nucleotides) or were tran-
scriptionally active with three nucleotides added to the
reaction (ATP, CTP, and GTP). In the latter case, the
polymerase normally stalls at the early stages of elonga-
tion. As a further set of controls, we utilized the clade B
LTR of wild-type, TATA+/TAR-, TATA-/TAR+, and AdML
promoters [53].
A limited number of proteins bound to the transcription-
ally inactive control promoters including histones H4,
H2A, H2B, and H3 (Figure 3A, lanes 4–7). Twenty pro-
teins that bound to the transcriptionally active HIV-1 LTR
were identified (Figure 3A, lane 10). The proteins identi-
fied included: 1) histone H4; 2) Tat; 3) histone H2A; 4)
histone H2B; 5) histone H3; 6) TFIIB; 7) cdk2; 8) cdk9; 9)
undetermined; 10A) cyclin E; 10B) cyclin E; 11) cyclin T;
12) undetermined; 13) undetermined; 14) undeter-
mined; 15) undetermined; 16) Sp1; 17) RNA helicase A;
18) RNAPII large subunit; 19) BRG1; and 20) DNA-PK.
Additionally, we performed control reactions using HXB2
HIV chromatin transcription at various stages of the cell cycle Figure 1
HIV chromatin transcription at various stages of the cell cycle. To obtain synchronized extracts, both eTat and con-
trol cells were first treated with hydroxyurea, released and then treated with nocodazole. Extracts were made from 1 h (G0), 
3 h (early G1), 6 h (G1/S), 15 h (late S), and 21 h (G2) post-nocodazole release and used in an in vitro transcription reaction. 
Released cells (1/10) were processed for FACS profile (data not shown). Two micrograms of chromatin DNA were used in 
each reaction. The bottom panels are gels of histones from immobilized DNA after transcription stained with Coomasie Blue. 
Lanes 1–5 and 11–15 are using eTat extract, and lanes 6–10 are using control pCEP4 extract. The left panel contains HIV-LTR-
TAR wild-type and HIV-LTR-TAR mutant (TM26), and 200 ng of naked DNA (AdLuc, [55]).
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HIV-1 Nef and Env expression in individual cells at various phases of the cell cycle Figure 2
HIV-1 Nef and Env expression in individual cells at various phases of the cell cycle. A) HIV-1 protein expression 
was monitored by flow cytometric analysis. OM10.1 cells were washed in Hanks' balanced salt solution, fixed in 70% ice-cold 
ethanol, and stained with mouse anti-human monoclonal antibodies to cyclin E, cyclin A, Nef, Env, or a non-specific immu-
noglobulin (DAKO) overnight. Cells in G1 and G2 were identified by DNA content and divided the intervening region into 10 to 
12 equal increments to allow the calculation of mean protein-associated fluorescence and mean DNA content. The exact same 
analysis was performed on the appropriate aliquot stained with non-specific immunoglobulin. Protein fluorescence was deter-
mined by subtracting the mean from the nonspecific samples. Samples were washed in PBS-BSA and stained with a fluorescein 
isothiocyanate-labeled goat anti-mouse secondary antibody (1:30; DAKO) for 30 min in the dark. The bottom of panel A 
shows HIV-1 gene expression in G0, early G1, G1/S, S, and G2 phases of cell cycle by RT-PCR with primers for Env and Nef [58, 
59]. B) Cell cycle analysis of cells after G0 release. Cells were synchronized at G0 by serum starvation and samples were 
removed from the medium at each time point, washed with PBS without Mg2+ or Ca2+, fixed with 70% ethanol, and stained 
with propidium iodide followed by cell-sorting analysis on a Coulter EPICS cell analyzer. The FACS profile for each time point 
is presented along with the percentage of cells in G1, S, and G2 (upper right side boxes of each histogram).
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TATA-/TAR+, HXB2  TATA+/TAR-, and AdML promoters
(Figure 3B). A number of unique proteins were bound to
the wild-type promoter that were not bound on the HXB2
TATA-/TAR+ and TATA+/TAR- promoters (data not shown).
Results in Figure 3A confirms published data showing that
TFIIB, cdk2, cdk9, cyclin E, cyclin T1, Sp1, RNAPII, and
DNA-PK associate with the HIV-1 LTR during basal tran-
scription or Tat activated transcription. These results also
showed that cdk9/cyclin T1 and other cyclin/cdk com-
plexes (i.e. cdk2/cyclin E) are involved in transcription of
the HIV-1 promoter. Finally, these results indicate that Tat
recruits a component of the chromatin remodeling com-
plex, BRG1, to the HIV-1 LTR.
Effect of acetylated Tat on recruitment of a chromatin 
remodeling complex
The identification of BRG1 as one of the proteins that
bound to transcriptionally active HIV-1 LTR suggests that
this component of the SWI/SNF complex may be impor-
tant in Tat activated transcription. To elucidate the role of
Identification of cellular proteins associated with the transcriptionally active nucleosomal HIV-1 promoter Figure 3
Identification of cellular proteins associated with the transcriptionally active nucleosomal HIV-1 promoter. A) 
Nucleosomes were assembled on biotin labeled HIV-1 LTR DNA and G1/S extracts were added to the reaction mixture. Fol-
lowing washes (TNE600 plus 1% NP-40), samples were eluted with excess biotin and centrifuged to pellet the beads. Superna-
tants were TCA precipitated and ran on a 4–20% gel and silver stained (MALDI compatible). Lane 1, Strepavidin beads; lane 2, 
purified core histones before nucleosomal assembly; lane 3, purified Tat; lanes 4–7 are LTR sequences (-110/+180) from four 
different clade B isolates assembled and incubated with G1/S extracts without any nucleotide addition; lane 8, transcriptionally 
active HXB2 promoter with nucleotide addition (ATP, CTP, GTP); lane 9, HXB2 promoter with purified Tat; lane 10 same as 
lane 8 with purified Tat; lane 11, the rainbow molecular marker (14–220 kDa). B) Control gel utilizing HXB2 wild-type, TATA-
/TAR+, and TATA+/TAR- promoters with Tat and nucleotide (ATP, CTP, GTP) and AdML promoters. Unique proteins (.) 
bound to DNA were cut out, trypsin digested, and used for identification by mass spectrometry [74].
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BRG1 in HIV-1 gene expression, we determined whether
there was a direct association with modified Tat. While the
detailed molecular mechanisms underlying Tat dissocia-
tion from TAR RNA and its trans-activation of transcrip-
tion on the integrated HIV-1 genome remain elusive,
increasing evidence suggests that Tat activity requires asso-
ciation with several multiprotein complexes, which
include the cyclin T1/cdk9 complex [33,36,43,63-69] and
the HAT transcriptional coactivators, p300/CBP and
p300/CBP-associated factor (p/CAF) [60,70,71]. The site
of acetylation of Tat was mapped to a double-lysine motif
in a highly conserved region (49RKKRRQ54) of the basic
RNA-binding motif of Tat. Tat acetylation resulted in its
dissociation from TAR RNA and promoted the formation
of a multiprotein complex comprised of Tat and p/CAF
[60,70]. Furthermore, we previously had shown that
immobilized biotin Tat or acetylated Tat at positions 41,
50, and 51 could selectively pull-down distinct functional
complexes including transcription-associated proteins,
acetyltransferase-associated proteins, and kinase proteins
[72].
We confirmed by Western blotting that the unmodified
peptide of Tat (aa 42–54) bound cyclin T1 while the
acetylated form of the Tat peptide bound BRG1. These
results were confirmed using full length Tat protein (Fig-
ures 4A and 4B). Additionally, we confirmed that
acetylated lyines 41, 50, and 51 of Tat are important for
BRG1 binding (Figure 4B, lanes 3 and 4). Results pre-
sented in panel A used CEM extracts and results in panel
B used purified cyclin T1/cdk9 and SWI/SNF complexes
(containing BRG1). To further validate these findings, we
decided to perform an in vitro binding assay using 35S-Tat
or 35S-BRG1. Two independent BRG1 domains were incu-
bated with 35S-Tat in vitro. BRG1-N spans the N-terminal
residues 1–282 and shows high sequence divergence from
the corresponding region of BRM. BRG1-C1 contains a 99
base pair exon that is unique to BRG1, the conserved E7
sequence, and a portion of the lysine-arginine region [73].
Results in panel C indicate that acetylated Tat was able to
bind efficiently to the BRG1-N terminal construct (lane 6)
and not the C-terminal domain (lane 3). Unacetylated Tat
did not bind BRG1 as efficiently as acetylated Tat (com-
pare lanes 5 and 7 to lane 6). We next performed the
reverse experiment, where GST-Tat was allowed to bind to
35S-BRG1  in vitro. As expected, the acetylated GST-Tat
bound to wild-type BRG1, while unacetylated Tat (wild-
type or 41/50/51 mutant) bound Tat much less efficiently
(lanes 3 and 5, respectively).
To determine whether these complexes bind HIV-1 DNA,
we utilized an in vitro transcription/assembly system [62],
where HIV-1 proviral LTR DNA was assembled into nucle-
osomal DNA prior to in vitro transcription. Nucleosomes
were first assembled on biotinylated HIV-1 LTR DNA tem-
plate and then immobilized using strepavidin agarose
beads. The immobilized chromatin LTR was washed in
acetylation buffer and used as a substrate for acetylation
by p300 in the presence or absence of Tat. Templates were
then washed in transcription buffer and used in an in vitro
run-off transcription reaction. Active complexes were
pulled-down, washed, ran on a 4–20% SDS/PAGE,
stained for the presence of histones and then western blot-
ted for the presence of cyclin T1 or BRG1. Results in Figure
4D indicate that the wild-type Tat acetylated by HAT was
able to efficiently bind to BRG1, consistent with results
from panel B, where there was no HIV-1 DNA present in
the reaction. Finally, to address whether these interactions
were functionally significant in a chromatin transcription
setting, we utilized the G1/S extract from CEM cells in an
in vitro transcription reaction. Similar to HeLa cells (data
not shown), CEM cells were treated with hydroxyurea/
nocodazole, and samples were processed at 9 h post-
release (G1/S) for in vitro transcription. The extracts were
supplemented with SWI/SNF (all lanes), plus wild-type
Tat (lanes 2 and 6), acetylated Tat (lanes 3 and 7), and
mutant Tat (50/51) (lanes 4 and 8). Naked AdLuc DNA
served as an internal control for transcription. As can be
seen in Figure 4E, only acetylated Tat allowed for a robust
transcription from the wild-type LTR (lane 3) and not the
mutant TAR template (lane 7). Furthermore, addition of
anti-acetyl Tat 50/51 antibodies (see Figure 5) at increas-
ing concentrations (panel E, 100, 300, and 500 ng; lanes
10–12) specifically inhibited transcription from the HIV-
1 template. Collectively, these results indicate that acety-
layted Tat has a high affinity to BRG1, and a combination
of both Tat and BRG1 (SWI/SNF) promote TAR-specific
HIV-1 transcription.
Presence of acetylated Tat and BRG1 on HIV-1 
nucleosomal DNA in vivo
To assess the functional relevance of Tat acetylation in
vivo, we performed a series of ChIP assays from HIV-1
infected cells. We first raised polyclonal antibodies against
acetylated Tat using acetylated Tat peptides as antigens.
These antibodies recognize Tat acetylation at lysine 41 or
50 and 51. Next, we transfected HLM-1 cells with a wild-
type Tat plasmid (eTat). These cells are HIV-1+/Tat-, thus
introduction of wild-type Tat allows for full trans-activa-
tion and viral progeny formation. When anti-acetyl-Tat
antibodies were used for immunoprecipitation, we con-
sistently observed an association of acetylated Tat at
regions where nuc-1 is located but not nuc-0 (Figure 5).
These data suggest that Tat is acetylated in vivo and is asso-
ciated with the nuc-1 region of the HIV-1 promoter, which
encompasses the transcription start site.
Effect of BRG1 on HIV-1 transcription in vivo
Tat recruitment of SWI/SNF to the HIV-1 LTR presumably
plays a role in the ability of Tat to trans-activate the pro-Retrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
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BRG1 binds to acetylated Tat Figure 4
BRG1 binds to acetylated Tat. A) CEM G1/S cell extracts (2 mg) were mixed with 100 μg of biotin-Tat peptides (aa 42–
54), incubated for 2 h, and washed. Bound proteins were separated on a 4–20% SDS/PAGE and Western blotted. Lane 1, input; 
lane 2, unacetylated Tat peptide; and lane 3, acetylated Tat peptide. B) GST-Tat (wild-type and mutant) was purified over a glu-
tathione column and eluted. Acetylated GST-Tat was incubated with p300 and acetyl-CoA (62), washed, and incubated with 
cyclin T1/cdk9 (top) or SWI/SNF (bottom). Bound complexes were run on a 4–20% SDS/PAGE and Western blotted for the 
presence of cyclin T1 or BRG1. Lane 1, wild-type Tat; lane 2, Tat with a lysine to arginine change at residues 41, 50, and 51; lane 
3, wild-type Tat and p300; lane 4, mutated Tat and p300. C) GST proteins and TNT lysates containing 35S-labeled Tat or BRG1 
were incubated for 2 h at 4°C. Complexes were centrifuged; bound labeled proteins were denatured, subjected to SDS-PAGE, 
dried, and autoradiographed. D) Top: Schematic of the biotinylated HIV-1 LTR DNA used in the pull-down assay. Bottom: 
Immobilized chromatin HIV-1 LTR templates were incubated with CEM extract and wild-type or mutated Tat, then acetylated 
in the presence of GST-HAT. Samples were incubated with 100 ng SWI/SNF and all four cold nucleotides. Templates were 
washed and proteins were separated on a 4–20% SDS/PAGE for Western blot analysis. Bottom: remaining histones after tran-
scription. E) CEM cells were treated with hydroxyurea and nocodazole, and samples were processed at 9 h post-release. The 
extracts were supplemented with purified SWI/SNF (all lanes), plus wild-type Tat (lanes 2 and 6), acetylated Tat (lanes 3 and 7), 
and Tat mutated at positions 50/51 (lanes 4 and 8). Anti-acetyl Tat 50/51 antibodies were added at time zero (lanes 10–12). 
Bottom: histone stain from immobilized DNA after transcription.
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moter and induce replication. To assess this possibility,
RNA interference (RNAi) of BRG1 expression in HIV-1
infected cells was used. Here, we synthesized a series of
wild-type and mutant siRNA against BRG1. We chose five
oligonucleotides that span the 5' end, middle, and 3' end
of the BRG1 mRNA. The sequences of the siRNA and the
nucleotide position are listed in Materials and Methods
and have previously been published [74]. The most opti-
mal sequences had a GC content of between 30%-70%
[74]. To assess the importance of BRG1 in viral transcrip-
tion, we utilized the HIV-1 chronically infected cell ACH2.
Viral induction in ACH2 cells was achieved by treatment
with TNF-α (Figure 6, left panel). Addition of increasing
amounts of wild-type BRG1 siRNA (a mixture of all five
oligonucleotides electroporated into cells) resulted in a
decrease in p24 expression. However, when mutant BRG1
siRNA was utilized, p24 expression and, hence HIV-1
progeny formation, was unaffected. Similar results were
obtained in other chronically infected cells including
OM10.1, 8E5 (Figure 6, right panels), and J1-1 as well as
U1 (data not shown). BRG1 protein expression was also
decreased as a result of the siRNA (wild-type) treatment;
Acetylated Tat associates with a chromatinized HIV-1 promoter at or near nuc-1 but not nuc-1 Figure 5
Acetylated Tat associates with a chromatinized HIV-1 promoter at or near nuc-1 but not nuc-1. A) Diagram of 
nucleosomes positioned on the integrated HIV-1 genome. The transcription start site is indicated as +1. Critical transcription 
factor binding sites (NF-κB, Sp1, and TBP) are indicated. Location of nuc-0 through nuc-4 are indicated above the diagram. B) 
ChIP analysis of the HIV-1 genome. The ChIP assay was performed as described [110, 111] with modifications (see Materials 
and Methods). HLM-1 cells (Tat-) [112] were transfected with the pCEP4/eTat vector [53] or no DNA and ChIP analysis was 
performed with anti- acetyl Tat 50/51 antibodies, anti-acetyl Tat 41 antibodies, or anti-acetyl H4 antibodies (positive control 
for acetylation of histones and association of nucleosomes with the HIV-1 promoter). The PCR primer pair location and 
expected sizes are indicated next to the expected amplified PCR products.
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mutant siRNAs did not affect BRG1 protein levels (Figure
6, bottom panel). These results indicate that BRG1 expres-
sion is critical for HIV-1 replication.
Next, we investigated whether BRG1 was in fact recruited
to the HIV-1 promoter in vivo. We transfected a BRG1
eukaryotic expression construct [74] into C33A cells that
had an HIV-1 reporter construct stably integrated into its
genome [75]. Cells were either left untreated, stimulated
with PMA, treated with the HDAC inhibitor TSA, or
exposed to both PMA and TSA. Following harvesting, a
ChIP assay was performed with antibodies against BRG1.
Immunoprecipitated DNA was analyzed by PCR with
primers specific for nuc-0 and nuc-1. Figure 7A shows that
BRG1 does interact with the nuc-0 region in vivo and that
this interaction is dependent upon presence of both PMA
and TSA (panel A top, lanes 7 and 11). The presence of
BRG1 on nuc-0 was not Tat dependent (lanes 8–10).
However, BRG1 was present on nuc-1 in the presence of
PMA or TSA (panel A bottom, lanes 5, 6, 9, and 10). More
importantly, BRG1 was present on nuc-1 in unstimulated
cells in the presence of Tat (compare lanes 4 and 8). A Tat
50/51 mutant did not recruit BRG1 to the nuc-1 site (data
not shown). Finally, since BRG1 is recruited to the nuc-1
region of the HIV-1 promoter in response to Tat expres-
sion alone, we investigated whether this recruitment stim-
Suppression of BRG1 expression by RNAi inhibits HIV-1 replication Figure 6
Suppression of BRG1 expression by RNAi inhibits HIV-1 replication. Complete sequence of BRG1 wild-type and 
mutant siRNA used in transfection. Oligos were designed and synthesized using the OligoEngine website [109]. HIV-1 infected 
cells (ACH2, OM10.1 and 8E5) were treated with TNF-α (10 ng/ml) for 2 h, washed, and subsequently electroporated (ACH2, 
[113]) or Amexa (OM10.1 and 8E5) treated with increasing amounts (1, 5, or 10 μg) of either wild-type (WT) or mutant (mut) 
BRG1 siRNA. Forty eight hours later, samples were collected and used for p24 gag ELISA. Western blot against BRG1 showed 
more than 90% decrease in protein levels in WT and not mutant BRG1 siRNA transfect cells [74].
0
50
100
150
200
250
300
350
400
450
500
G
a
g
 
P
2
4
 
(
n
g
/
m
l
)
-
+
- - - - - - - - - - - - - - - BRG-1 (siRNA, mut)
- - - - - - - - - - - - - - BRG-1 (siRNA, WT)
+ + + + + + + - + + + + + + + - + + + + + + - TNF
-
+
- - - - - - - - - - - - - - - BRG-1 (siRNA, mut)
- - - - - - - - - - - - - - BRG-1 (siRNA, WT)
+ + + + + + + - + + + + + + + - + + + + + + - TNF
ACH2 OM10.1 8E5
Actin
BRG1
1    2    3    4    5    6    7 1    2    3    4    5    6    7 1    2    3    4    5    6    7Retrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
Page 11 of 19
(page number not for citation purposes)
BRG1 and Tat associate with chromatinized HIV-1 promoter in C33A cells at nuc-1 Figure 7
BRG1 and Tat associate with chromatinized HIV-1 promoter in C33A cells at nuc-1. A) The BRG1/hBrm-deficient 
cervical carcinoma cell line C33A was used for these experiments and maintained under standard conditions in Dulbecco's 
modified Eagle's medium. A BRG1 (10 μg) or Tat (3 μg) expression vector or a control vector (10 μg, lane 3) was transfected 
into C33A cells that have an HIV-1 reporter construct stably integrated into their genome. After cells were allowed to express 
BRG1 for 36 h, cultures were stimulated with either PMA for 2 h (lane 5), TSA for 12 h (lane 6), or both for 2 h and 12 h, 
respectively (lane 7), before ChIP. A ChIP assay was performed with BRG1 antibodies, and PCR was used to detect the recov-
ery of nuc-0 and nuc-1 DNA. The input DNA represents the total genomic DNA. Ab, antibody; Unstim, unstimulated. B) 
BRG1 and Tat were transiently expressed in C33A cells that had been stably transfected with an HIV-1-luciferase construct. 
Thirty-six hours after transfection, cells were stimulated with either PMA for 2 h, TSA for 12 h, or both for 12 h. Following 
stimulation, cells were lysed, and the luciferase activity was measured [114]. Data presented is from average of two individual 
experiments.
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ulated transcription. C33A cells containing a stably
integrated HIV-1 luciferase reporter construct were tran-
siently transfected with the BRG1, Tat, or BRG1 and Tat
expression constructs or a control vector (Mock). Figure
7B shows that without BRG1 or Tat; PMA, TSA or PMA
and TSA stimulated HIV-1 luciferase transcription any-
where from 3- to 14-fold. However, in the presence of
both Tat and BRG1 the stimulation increased from 28- to
89-fold above background, implying that to recover
robust activated transcription, the integrated HIV-1 pro-
moter requires both Tat and BRG1. This also indicates that
a factor required for a high level of HIV-1 reporter expres-
sion is limiting in C33A cells. Hence, we concluded that
Tat acetylation, followed by BRG1 recruitment, plays an
important role in stabilizing the interaction between SWI/
SNF and HIV-1 chromatin resulting in remodeling of nuc-
1 and activated viral transcription.
Effect of BRG1 and acetylated Tat on nucleosomes on the 
HIV LTR
A number of investigators, including the Verdin lab, have
performed pioneering experiments to define the nucleo-
some positions in HIV-1 infected cells. The HIV-1 genome
was first analyzed for the presence of DNase-I hypersensi-
tive sites using an indirect end-labeling technique [45].
Three well characterized, chronically infected cell lines,
ACH2, 8E5, and U1, were used to define nucleosome
boundaries. Five major hypersensitive sites were identi-
fied, some of which were common among the three cell
lines. They included DNase-I hypersensitive sites at the 5'
LTR, namely HS2 (nt 223–325), HS3 (nt 390–449), and
HS4 (nt 656–720) [46]. Both HS3 and HS4 are at the 5'
and 3' boundaries of nucleosome-1 (nuc-1), respectively.
Nuc-1 is located at the transcriptional start site and poses
a block to activated transcription [76]. However, when
activated transcription occurs, there is a disappearance of
the periodic DNA protection pattern following digestion
with DNase-I and reveals a profile of digested template
essentially identical to naked DNA [46]. Therefore, nuc-1
is disrupted when activated transcription takes place in all
three cell lines tested [45,46,76-80].
We then determined whether BRG1 and/or acetylated Tat
are responsible for removing nuc-1, and whether we could
faithfully mimic the in vivo data in an in vitro remodeling
assay. We used two LTR sequences spanning 800 bp from
the 5' U3 region into the Gag region. Sequences from
clades B and E were PCR amplified with biotin-labeled
primers, assembled into nucleosomes, and mixed with
CEM G1/S extracts for in vitro transcription. To facilitate
chromatin remodeling, we also added SWI/SNF, Tat, or
acetylated Tat to the reaction. Following transcription,
immobilized templates were pulled-down, washed, and
used for restriction enzyme digestion (Afl II). Afl II cleaves
at position 520 at the end of the R (TAR) region. The Afl II
site is normally blocked if nuc-1 is present; however, the
site becomes accessible if the nucleosome is remodeled or
removed. Therefore, if Afl II is able to cleave the DNA,
then a 3' fragment consisting of U5 and Gag will be
released into the supernatant and the fragment can be
detected by Southern analysis using a probe spanning the
U5/Gag region. A diagram of the experiment is illustrated
in Figure 8A while the results are shown in Figure 8B. The
presence of CEM G1/S extracts and SWI/SNF allowed a
low level of digestion with Afl II, and Tat increased acces-
sibility by 3-fold (panel B, second line). However, in the
presence of SWI/SNF and acetylated Tat, Afl II digestion
was increased 13- to 15-fold for the LTRs of clades B and
E (panel B, third line). The increase in digestion was spe-
cific to a combination of SWI/SNF and acetylated Tat,
since neither complex alone dramatically increased acces-
sibility. Finally, in the presence of a RNAPII inhibitor, α-
amanitin, there was no Afl II digestion, indicating that
active RNAPII transcription was needed for nuc-1 removal
and Afl II accessibility. No increase in Afl II digestion was
observed on the TAR mutant template (panel B, right
side). Collectively, these results indicate that in vitro
reconstitution of at least few nucleosomes on the LTR
mimics the in vivo positioning of HIV-1 nucleosomes as
seen in latently infected cells, and that the presence of
SWI/SNF and acetylated Tat are sufficient to remodel/
remove the blocking nuc-1 nucleosome on the HIV-1 LTR.
Discussion
The chromatin structure presents a significant barrier to
transcription. Various complexes, including HATs, cova-
lently modify nucleosomal histone proteins through
acetylation while ATP-dependent chromatin remodelers
alter the chromatin structure via ATP hydrolysis. These
modifications and alterations of chromatin structure
increase DNA accessibility to transcription factors and
activators thus promoting transcription initiation and
efficient elongation. A more current view is that activators
must first recruit chromatin remodelers in order to create
a chromatin environment permissive for pre-inititation
complex (PIC) assembly. Recently, it has become evident
that other factors, such as the chromatin structure of the
gene promoter and the phase of the cell cycle, also govern
how chromatin remodelers collaborate with each other to
control steps before, during, or after PIC assembly.
Although the precise nucleosome position of the inte-
grated HIV-1 LTR is well characterized, there is little data
about how this primary structure is folded into the chro-
matin fiber or other secondary structures (>30 nm fiber)
and how these structures influence HIV-1 latency and
transcriptional activation. Few studies have shown that
the integration site and its corresponding chromatin envi-
ronment affect HIV-1 gene expression [81,82]. Sequence
analysis and mapping of HIV-1 integration sites in the cel-Retrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
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Effect of SWI/SNF, Tat, or acetylated Tat on restriction enzyme accessibility Figure 8
Effect of SWI/SNF, Tat, or acetylated Tat on restriction enzyme accessibility. A) A diagram of the transcription 
experiment. Immobilized templates (800 bp from the 5' U3 region and into the Gag region) were assembled into nucleosomes 
and SWI/SNF, Tat, or acetylated Tat were added to the reaction. In the absence of transcription, nuc-1 blocks restriction 
enzyme accessibility of Afl II. During transcription and remodeling of the nucleosome, the Afl II site becomes accessible, and the 
3' end sequence is released. This fragment can be detected by southern slot blotting [74] using a probe (end labeled oligonucle-
otide) spanning the U5 region into Gag. B) In vitro transcription using CEM cells (G1/S extract). Similar to Figure 1, CEM cells 
were treated with hydroxyurea/nocodazole and samples were processed at 9 h post-release. The extracts (EXT, 200 μg) were 
supplemented with 200 ng of purified SWI/SNF, plus wild-type Tat (500 ng), or acetylated Tat (500 ng). α-amanitin at 0.1 μg/ml 
was used to detected RNAPII sensitivity. Clades B and E (a generous gift of J. Hiscott) and the TAR mutant LTR (TM26) were 
used as the DNA templates.
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lular genome has provided evidence that chromatin struc-
ture plays an important role in subsequent HIV-1
transcription. Analysis of the site of integration during
productive HIV-1 infection has shown that integration
preferentially occurs in areas rich in retrotransposable Alu
elements [83-85] and transcriptionally active genes (69%
of 524 integration sites) [83]. These areas are character-
ized by increased chromatin accessibility and the accumu-
lation of factors important for chromatin remodeling.
These data are also consistent with earlier observations
that sites which are preferentially accessible to DNase-I are
favored for integration [86-89]. However, a small fraction
of cells (less than 1%) exhibited post-integration latency,
a state of transcriptional silencing.
Many reports in the last several years have linked Tat trans-
activation to chromatin remodeling in vitro and in vivo.
When transcription is activated by Tat in a LTR integrated
cell line, the chromatin associated with sequences imme-
diately downstream of the transcription start site become
accessible to nucleases and the nucleosome adjacent to
the transcription start site (nuc-1) becomes disrupted
[78]. Similarly, transfection of Tat into Jurkat (Tat-) clones
containing a integrated single HIV-1 mini-genome acti-
vated HIV-1 transcription and resulted in the disruption
of nuc-1 to the same extent as TSA treatment [82]. Further-
more, immunoprecipitation of Tat from human cells
identified a protein complex with HAT activity, suggesting
that HATs are targeted to the HIV-1 promoter by Tat [90].
Interestingly,  in vitro transcription from chromatinized
templates indicated that Tat trans-activation is synergistic
with Sp1 and NF-κB [48]. In vivo, HIV-1 LTR lacking Sp1
and NF-κB sites do not undergo chromatin remodeling
and are unresponsive to Tat trans-activation [78]. Several
other groups have observed that Tat is able to form a ter-
nary complex with several HAT complexes, including
p300/CBP, p/CAF, TAFII250, and Tip60, targeting these
HAT proteins to the viral promoter [70,90-94].
Similar to our findings, two recent reports have shown the
involvement of SWI/SNF as a cofactor for Tat activation of
the HIV promoter. Tréand et al. [95] showed that, via its
arginine-rich motif, Tat was able to interact with Brm, the
enzymatic subunit of the SWI/SNF chromatin-remodeling
complex. This interaction was regulated by Tat acetylation
at lysine 50. Tat recruited the SWI/SNF complex to the LTR
in vivo, leading to the activation of the integrated HIV-1
promoter. Another recent report from the Verdin lab also
showed similar results [96]. Knockdown of INI-1 and
BRG1, two components of the SWI/SNF chromatin-
remodeling complex, suppressed Tat-mediated trans-acti-
vation, and cells deficient in INI-1 or BRG1 exhibited
defective Tat trans-activation. Tat was found to be in com-
plex with several SWI/SNF subunits, and the complex syn-
ergized with p300 to activate the HIV-1 promoter. A
recent study from the Trono lab revealed that INI1 uses its
repeat domains (Rpt 1 and 2) to bind and subsequently
enhance the trans-activation potential of Tat [97]. While
INI1 is dispensable for viral transduction, their findings
suggest that incoming PIC might recruit INI1 to promote
chromatin remodeling at the HIV-1 promoter and
enhance transcription.
It is interesting to note that INI-1 (Snf5/BAF47) is also a
potent tumor suppressor whose mechanism of action is
largely unknown. Tumor suppressor activity of Snf5
depends on its regulation of cell cycle progression; Snf5
inactivation leads to aberrant up-regulation of E2F targets
and increased levels of p53 that are accompanied by apop-
tosis, polyploidy, and growth arrest. Furthermore, condi-
tional mouse models demonstrate that inactivation of
p16Ink4a or Rb does not accelerate tumor formation in
Snf5 conditional mice, whereas mutation of p53 leads to
a dramatic acceleration of tumor formation [98]. There-
fore, it would be interesting to further determine if the
binding of Tat to the SWI/SNF complex (either through
INI-1 or BRG1) could somehow control the expression of
cell cycle genes (i.e., G1/S genes) and alter their activity.
Current experiments are in progress to address this critical
issue and whether G1/S genes such as various cyclins,
including the cyclin E and T promoters, are modulated by
the Tat/SWI/SNF complex.
We and others have shown that Tat can be acetylated at
lysines 28, 50, and 51 leading to altered interactions
between Tat and TAR, p300/CBP, and p/CAF, as well as
activation of viral transcription and replication. They col-
lectively support the notion that Tat first recruits p300/
CBP to the HIV-1 promoter during initiation. Tat
acetylated at lysine 50 then recruits p/CAF, which subse-
quently acetylates Tat at lysine 28. Acetylation of Tat at
lysines 50 and/or 51 promotes the dissociation of Tat
from TAR RNA and contributes to stimulation of tran-
scription elongation [60,99]. The acetylated form of Tat is
released from TAR, which can now bind to BRG1, a com-
ponent of the SWI/SNF chromatin remodeling complex.
We hypothesize that the interaction of Tat with BRG1
facilitates SWI/SNF to remodel downstream nucleosomes
allowing for further transcription of the HIV-1 genome.
We propose that the major function of the interactions
between Tat and bromodomain proteins is to modify
HIV-1 chromatin such that the LTR becomes responsive to
Tat and allows ample and rapid activated transcription to
occur. This also may set the stage for re-initiation of tran-
scription where pre-made (activated) complexes may be
recycled for HIV-1 activated transcription. Future experi-
ments will address these particular issues along with Tat's
effect on the remodeling activity of the SWI/SNF complex
at the proximal promoter and ORF regions of HIV-1
genome.Retrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
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Materials and methods
Cell culture
ACH2 and 8E5 cells are both HIV-1-infected lymphocytic
cells, with a single integrated wild-type copy (ACH2) and
a single integrated copy containing a defective reverse
transcriptase (8E5) in CEM (12D7) cells. The CEM T cell
(12D7) is the parental cell for both ACH2 and 8E5 cells.
U1 is a monocytic clone harboring two copies of the viral
genome from parental U973 cells. All cells were cultured
at 37°C with up to 1 × 105 cells per ml in RPMI 1640
media containing 10% fetal bovine serum (FBS), 1%
streptomycin/penicillin antibiotics, and 1% L-glutamine
(Gibco-BRL, Carlsbad, CA). HLM-1 cells (AIDS Research
and Reference Reagent Program, Catalog No. 2029) were
derived from HeLa-T41 cells integrated with one copy of
the HIV-1 genome containing a Tat-defective mutation.
The mutation was introduced as a triple termination
linker at the first AUG of the Tat gene. HLM-1 cells are
completely negative for virus particle production, but can
be induced to express one cycle of infectious HIV-1 parti-
cles after transfection with Tat cDNA or mitogens such as
TNF-α or sodium butyrate. HLM-1 cells were grown in
DMEM containing 10% FBS, 100 mg/ml of G418, plus
1% streptomycin/penicillin, and 1% L-glutamine (Gibco
BRL). Cells were grown to 75% confluency prior to the
transfection. Plasmids were transfected into HLM-1 cells
by electroporation or Amexa, washed after 4 h, and re-fed
with fresh complete DMEM with 10% FBS for the remain-
der of the experiment.
Generation of epitope-tagged Tat-expressing cell line
HeLa CD4+ cells were used for transfection with either an
epitope-tagged (the influenza epitope at the C-terminus
of Tat 1–86) plasmid or the parental vector pCEP4. Fol-
lowing transfection, cells were selected with 200 μg of
hygromycin/μl. Hygromycin-resistant lines established
from single-cell clones were maintained for up to 12
months with continuous passage and used to make
extracts for in vitro transcription analysis [53].
ChIP assays
Five to ten million infected cells in log phase were incu-
bated for 2 h with or without 5 μg/ml TNF-α to induce
transcription of latent proviral DNA. Cells were subse-
quently left untreated or treated with siRNA. After 48 h,
cells were cross-linked (1% formaldehyde, 10 min at
37°C) and samples were sonicated to reduce DNA frag-
ments to 200–800 nt lengths for ChIP assays. Specific
transcription complexes were immunoprecipitated with
appropriate antibodies. DNA sequences in the immuno-
precipitates were detected by PCR using primers specific
for the HIV-1 LTR (forward primer, 5'-ACTTTTCCG-
GGGAGGCGCGATC-3'; reverse primer, 5'-GCCACT-
GCTAGAGATTTCCACACTG-3') or Env region (forward
primer, 5'-CCTTG(T)GAGCCAATTCCCATA-3'; reverse
primer, 5'-TAACAAATGCTCTCCCTGGTC-3').
MALDI-TOF analysis
Individual protein bands were excised from the silver-
stained gel and destained with a solution of 30 mM potas-
sium ferricyanide/100 mM sodium thiosulfate (1:1) (v/v).
Trypsin-digested sample solutions were further desalted
and concentrated with C18 ZipTips (Millipore, Framing-
ham, MA). Samples were mixed with the same volume of
the matrix solution (α-cyano-4-hydroxycynnamic acid in
50% acetonitrile/0.1% [v/v] trifluoroacetic acid). Two
microliters of the mixtures were applied to the sample
plate and introduced into the mass spectrometer after dry-
ing. Mass spectra were recorded in the reflectron mode of
a MALDI-TOF mass spectrometer (Voyager-Elite; PerSep-
tive Biosystems) by summing 200–300 laser shots with an
acceleration voltage of 20 kV, 70% grid voltage, 0.05
guide wire voltage, 100 ns delay, and low mass gate at 700
m/z. Proteins were identified using the peptide mass fin-
gerprinting analysis software ProFound [101]. The
NCBInr database was used for the searches with several
passes of searching with different limitations for each
spot. In general, all bands were searched using methio-
nine oxidation and no limitation for pI as criteria. The
most optimal match for each spot was considered using
higher coverage rate, more matched peptides, and higher
score without limitations on the taxonomic category and
protein mass. Zero missed cleavage by trypsin and lowest
mass tolerance, i.e. ± 50 ppm, were considered for most of
the proteins. A few bands were searched with the follow-
ing parameters to find the best match: two missed cut
cleavages, limited to the "mammal" category, and/or a set
± 50% of total molecular mass. We consistently used mul-
tiple parameters such as low miss cut, low ppm, and first
methionine oxidation in our searches to obtain reliably
matched proteins. Identified proteins (i.e., Sp1, TFIIB,
cdk9, Tat, and BRG1) were confirmed by Western blot
analysis. Unless stated specifically, all data bases and tools
used for bioinformatics analysis were from the following
public websites: PubMed [102], ExPASy [103], BLAST
[104], Pfam [105], PBIL [106], COILS [107], and PIR
[108].
siRNA analysis
Oligonucleotides were designed and synthesized using
the OligoEngine website [109] and the accession number
for BRG1. Five oligonucleotides (see below), which span
the 5' end, middle, and 3' end of the BRG1 mRNA, were
chosen. The most optimal sequences had a GC content
between 30% and 70%. HIV-1 infected cell lines were
treated with TNF-α for 2 h. A mixture of the five oligonu-
cleotides was electroporated into the cells, and HIV-1 rep-
lication was monitored by p24 Gag enzyme-linked
immunosorbent assay (ELISA). The sequences of oligonu-Retrovirology 2006, 3:48 http://www.retrovirology.com/content/3/1/48
Page 16 of 19
(page number not for citation purposes)
cleotides used for BRG1 siRNA (wild-type) were as fol-
lows: [GenBank:U29175] -1716,
GGACAAGCGCCUGGCCUAC; [GenBank:U29175] -
2142, GAAGAUUCCAGAUCCAGAC; [GenBank
:U29175] -3210, GAUCUGCAACCACCCCUAC; [Gen-
Bank:U29175] -4236, GCAGUGGCUCAAGGCCAUC;
[GenBank:U29175] -4776, GGAGGAUGACAGU-
GAAGGC. The sequences used for BRG1 siRNA (mutant)
were as follows: [GenBank:U29175] -1716,
GGACAAAAAAAUGGCCUAC; [GenBank:U29175] -
2142, GAAGAUUCCAAAAAAAGAC; [GenBank:U29175]
-3210, GAUCUGCAACCAAAAAUAC; [Gen-
Bank:U29175] -4236, GCAGUGGCUCAAAAAAAUC;
[GenBank:U29175] -4776, GGAGGAU-
GAAAAAAAAGGC.
Cell cycle analysis
The eTat, control (pCEP4), CEM, and OM10.1 cells were
either blocked with hydroxyurea for 18 h or blocked with
hydroxyurea (2 mM final concentration), washed, and
released for 1 h, followed by addition of nocodazole (50
ng/ml) for 14 h. Following the block, the cells were
washed twice with phosphate-buffered saline (PBS) and
released with complete medium. Samples were collected
every 3 h, and the cells were used to make whole-cell
extracts (5 × 107 cells/time point) for in vitro transcription
or Western blot analysis or processed for fluorescence-
activated cell sorting (FACS). Single-color flow cytometric
analysis of DNA content was performed on various cell
lines. The cells were washed with PBS, and approximately
2 × 106 cells were fixed with 500 μl of 70% ethanol. The
cell pellets were washed three times with PBS and incu-
bated in 1 ml of PBS containing 150 μg of RNase A
(Sigma)/ml and 20 μg/ml of propidium iodide (Sigma, St.
Louis, MO) at 37°C for 30 min. The stained cells were
analyzed for red fluorescence (FL2) on a FACScan (Becton
Dickinson, San Jose, CA), and the distribution of cells in
the G1, S, and G2/M phases of the cell cycle was calculated
from the resulting DNA histogram with Cell FIT software,
based on a rectangular S-phase model.
In vitro transcription
In vitro transcription was performed with HeLa or CEM
whole-cell extracts (25 to 50 μg total) on immobilized
HIV-1 LTR chromatin templates which were assembled as
described below. The DNA fragments were biotinylated,
gel purified, and reconstituted with core histones by step
dilution. Briefly, core histones were purified from HeLa
cells and mixed with DNA. The biotinylated mononucle-
osome were prepared by mixing the biotinylated DNA
and purified core histones by sequential dilution from 1
to 0.1 M NaCl and subsequently phased. The biotinylated
nucleosomal arrays were then incubated at 30°C for 1 h
with paramagnetic beads coupled to streptavidin in a
binding buffer containing 10 mM HEPES (pH 7.8), 50
mM KCl, 5 mM DTT, 5 mM phenylmethylsulfonyl fluo-
ride, 5% glycerol, 0.25 mg/ml bovine serum albumin
(BSA), and 2 mM MgCl2, supplemented with 300 mM
KCl. In vitro transcription reactions were incubated for 1 h
at 30°C and contained the nucleoside triphosphates ATP,
GTP, and CTP at a final concentration of 50 μM and
[32P]UTP (20 μCi; 400 Ci/mmol; Amersham, Piscataway,
NJ) in buffer D (10 mM HEPES [pH 7.9], 50 mM KCl, 0.5
mM EDTA, 1.5 mM dithiothreitol, 6.25 mM MgCl2, and
8.5% glycerol). Transcription reactions were terminated
by the addition of 20 mM Tris-HCl (pH 7.8), 150 mM
NaCl, and 0.2% SDS. The quenched reactions were
extracted with equal volumes of phenol-chloroform and
precipitated with 2.5 volumes of ethanol and 1/10volume
of 3 M sodium acetate. Following centrifugation, the RNA
pellets were resuspended in 8 μl of formamide denatura-
tion mix containing xylene cyanol and bromophenol
blue, heated at 90°C for 3 min, and seperated at 400 V in
a 10% polyacrylamide (19:1 acrylamide-bisacrylamide)
gel containing 7 M urea (pre-ran at 200 V for 30 min) in
1 × Tris-borate-EDTA. Transcript sizes of 250 nt for AdLuc
and 375 nt for HIV-1 transcripts were observed. The gels
were analyzed with the Molecular Dynamics Phos-
phorImager screen and radioactivity was quantitated with
ImageQuant.
Immunofluorescence staining by flow cytometry
OM10.1 cells were used to analyze HIV-1 gene expression
at various stages of the cell cycle. Following arrest of cells
at G0 by serum starvation, cells were washed in Hanks'
balanced salt solution and fixed in 70% ice-cold ethanol.
After fixation, cells were rehydrated in PBS containing 1%
BSA and aliquots containing 0.5 × 106 to 1 × 106 cells were
resuspended in 150 μl of PBS-BSA. The abundance of Nef,
Env, cyclin E and cyclin A were determined after immun-
ofluorescence staining [56]. Cells were stained with
mouse anti-human monoclonal antibodies to cyclin E
(1:100; SC, clone HE67), cyclin A (1:50; SC, clone
BF683), Nef (1:50; AIDS reagent catalog, EH1), and Env
(1:50; AIDS reagent catalog, 48 d) or a nonspecific immu-
noglobulin (DAKO) overnight. Samples were washed in
PBS-BSA and stained with a fluorescein isothiocyanate-
labeled goat anti-mouse secondary antibody (1:30;
DAKO) for 30 min in the dark.
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